Abstract
The 32nd Hatfield MedChem 1-day virtual symposium organized by the Royal Society of Chemistry (RSC) Biological and Medicinal Chemistry Sector, was attended virtually by 130 delegates from different pharmaceutical and drug discovery companies, along with scientists from universities, mainly from the U.K. A total of 24 exhibitors supported the event organization, with 4 providing short oral presentations throughout the day. For this edition, networking table sessions were organized through the Grapevine platform to facilitate meetings with the speakers and interactions between all attendees and exhibitors. Sessions focused on relevant topics of current drug discovery such as protease inhibitors for the treatment of COVID-19, glue degraders as next-generation of PROTAC molecules, allosteric inhibition to circumvent cancer drug resistance and new strategies for targeting DNA damage response. Other sessions included fragment-based drug discovery approaches and specific CYP3A4 drug-metabolism optimization.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
